Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 18 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Losmapimod (Primary)
Indications COVID 2019 infections; Inflammation
Focus Registrational; Therapeutic Use
Acronyms LOSVID
Sponsors Fulcrum Therapeutics

Most Recent Events

16 Jul 2021 Planned End Date changed from 1 Jun 2021 to 1 Jul 2021.
16 Jul 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Jul 2021.
04 Mar 2021 According to a Fulcrum Therapeutics media release, an independent data safety monitoring board did not identify any safety concerns related to losmapimod.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com